FDA Position on Allowing Patients with ALS Acess to Iplex (mecasermin rinfabate recombinant) Under an IND

FDA Position on Allowing Patients with ALS Access to Iplex
(mecasermin rinfabate recombinant) Under an IND

Today, the Food and Drug Administration is sharing with the public its decision to allow patients with Amyotrophic Lateral Sclerosis, a fatal neurodegenerative disease also known as Lou Gehrig’s Disease, or ALS, to have access to a drug called Iplex under an Investigational New Drug (IND) application.

abrir aquí:
FDA Position on Allowing Patients with ALS Acess to Iplex (mecasermin rinfabate recombinant) Under an IND